| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10009794 | HBV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS10036366 | HBV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058841 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058842 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058843 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058844 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058845 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058846 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058847 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058848 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BCHE |
|---|---|
| DrugBank ID | DB00989 |
| Drug Name | Rivastigmine |
| Target ID | BE0002180 |
| UniProt ID | P06276 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 11078030; 11139819; 19370562; 16437532; 19470293; 19420308; 19374459; 18671661; 18044073; 14587496; 12636181; 34269114 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.@@Gottwald MD, Rozanski RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999 Oct;8(10):1673-1682.@@Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.@@Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.@@Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.@@Smith DA: Treatment of Alzheimer's disease in the long-term-care setting. Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622.@@Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs. 2009;23(4):293-307.@@Lalli S, Albanese A: Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother. 2008 Aug;8(8):1181-8. doi: 10.1586/14737175.8.8.1181.@@Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2(1):17-32.@@Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4.@@Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14 Suppl 1:77-91.@@Li S, Li AJ, Travers J, Xu T, Sakamuru S, Klumpp-Thomas C, Huang R, Xia M: Identification of Compounds for Butyrylcholinesterase Inhibition. SLAS Discov. 2021 Dec;26(10):1355-1364. doi: 10.1177/24725552211030897. Epub 2021 Jul 16. |
| Groups | Approved; Investigational |
| Direct Classification | Phenoxy compounds |
| SMILES | CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C |
| Pathways | |
| PharmGKB | PA451262 |
| ChEMBL | CHEMBL636 |
